Asthma
|
0.250 |
Biomarker
|
disease |
BEFREE |
In silico functional characterization of the asthma-associated SNPs also supported the contribution of C3AR1 and additional genes including SYNE1, LINGO2, and IFNG-AS1.
|
27445529 |
2016 |
Asthma
|
0.250 |
Biomarker
|
disease |
RGD |
Use of monoclonal antibodies to assess expression of anaphylatoxin receptors in rat and murine models of lung inflammation.
|
17544263 |
2007 |
Asthma
|
0.250 |
GeneticVariation
|
disease |
BEFREE |
Support for a causal role for altered anaphylatoxin production in human disease comes from reports of exaggerated complement production in the lungs of asthmatics as well as the association of asthma with polymorphisms in C3/C3aR genes.
|
16091207 |
2005 |
Asthma
|
0.250 |
AlteredExpression
|
disease |
LHGDN |
Complement factors c3a, c4a, and c5a in chronic obstructive pulmonary disease and asthma.
|
15039137 |
2004 |
Asthma
|
0.250 |
GeneticVariation
|
disease |
BEFREE |
A patient-only association study suggested that severity of childhood BA was associated with 1526G/A of the C3AR1 gene (P = 0.0057).
|
15278436 |
2004 |
Asthma
|
0.250 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrate the expression of C3aR and C5aR by cells endogenous to the lung, and, given the participation of bronchial epithelial and smooth muscle cells in the pathology of diseases such as sepsis and asthma, the data suggest a role for these receptors during lung inflammation.
|
11160252 |
2001 |
Lung diseases
|
0.200 |
Biomarker
|
group |
RGD |
Use of monoclonal antibodies to assess expression of anaphylatoxin receptors in rat and murine models of lung inflammation.
|
17544263 |
2007 |
Respiratory Distress Syndrome, Adult
|
0.200 |
Therapeutic
|
disease |
RGD |
Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats.
|
16782534 |
2006 |
Reperfusion Injury
|
0.200 |
Biomarker
|
disease |
RGD |
Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury.
|
15159277 |
2004 |
HEMOLYTIC UREMIC SYNDROME, ATYPICAL, SUSCEPTIBILITY TO, 1
|
0.100 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
We conclude that the C3aR antagonist, SB 290157, may be used in the future to limit the neuronal death by limiting secondary phagocytosis after stroke.
|
31814819 |
2019 |
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
Complement C3a receptor (C3aR) is a key mediator of post-ischemic cerebral injury, and pharmacological antagonism of the C3a receptor is neuroprotective in stroke.
|
31138990 |
2019 |
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
The development of tissue-specific C3aR knockout mice and more specific C3aR antagonists is warranted to facilitate our understanding of the role of the C3aR in brain ischemia with the ultimate goal of clinical translation of therapies targeting C3aR in stroke patients.
|
31102134 |
2019 |
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
The pathophysiological relevance of C3aR was scrutinized with the use of disease models of myocardial infarction and stroke.
|
29802205 |
2018 |
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Thus, whilst the C3aR modulates some elements of disease pathogenesis, overall it is not critical in effector responses and glomerular injury caused by autoimmunity to MPO.
|
29315316 |
2018 |
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Complement 3a receptor (C3aR) and complement 5a receptor (C5aR) have been reported to be involved in T cell mediated autoimmune disease.
|
29138505 |
2017 |
Autoimmune Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Complement activation products C3a and C5a have broad pro-inflammatory potential through their receptors, C3aR and C5aR, and contribute to the pathogenesis of several inflammatory and autoimmune diseases, but their roles in IgAN are poorly defined.
|
24327134 |
2014 |
Obesity
|
0.020 |
Biomarker
|
disease |
BEFREE |
We conducted a structure-function relationship study on the neuropeptide TLQP-21, a promising target for obesity, and its complement 3a receptor (C3aR1).
|
31484069 |
2019 |
Alzheimer's Disease
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Strikingly, this C3aR network includes multiple genes linked to late-onset AD.
|
30415998 |
2018 |
Impaired cognition
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here we show that the expression of C3 and C3a receptor (C3aR1) are positively correlated with cognitive decline and Braak staging in human AD brains.
|
30415998 |
2018 |
Coronary Artery Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
We found a strong positive correlation of platelet complement C3aR expression with activated glycoprotein IIb/IIIa in patients with coronary artery disease and coexpression of C3aR with glycoprotein IIb/IIIa in thrombi obtained from patients with myocardial infarction.
|
29802205 |
2018 |
Obesity
|
0.020 |
Biomarker
|
disease |
BEFREE |
The neuropeptide TLQP-21 opposes obesity via C3aR1-mediated enhancement of adrenergic-induced lipolysis.
|
28123945 |
2017 |
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Here we report that astrocytic complement activation also regulates Aβ dynamics in vitro and amyloid pathology in AD mouse models through microglial C3aR.
|
26758846 |
2016 |
Septicemia
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results highlight a novel role for complement and the Cpb1-C3-C3aR pathway in proinflammatory signaling, caspase-11 cell death, and sepsis severity.
|
27697835 |
2016 |
Sepsis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results highlight a novel role for complement and the Cpb1-C3-C3aR pathway in proinflammatory signaling, caspase-11 cell death, and sepsis severity.
|
27697835 |
2016 |